United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

What You Need to Know About COVID Vaccine Investing Right Now

The COVID-19 vaccine co-developed by Pfizer and BioNTech works against lab-made coronaviruses that are similar to the variants found in the UK and South Africa, the drugmakers announced Wednesday. Studies conducted by Pfizer and the University of Texas showed "small differences" in how well antibodies produced by Pfizer's vaccine bound to and killed the lab-made viruses, compared to how well they worked against the original virus.

Pfizer says its vaccine works against key mutations on the coronavirus variants found in South Africa and the UK

Pfizer Inc PFE , in a preliminary lab study, found that its COVID-19 vaccine co-developed by BioNTech SE BNTX is effective against the new mutation variants found in the U.K. and South Africa, the Wall Street Journal reported.

Preliminary Study Finds Pfizer's COVID-19 Vaccine Effective Against UK, South Africa Variants

BioNTech SE

Which stock will be the bigger winner between these two COVID-19 vaccine partners?

Better Buy: Pfizer vs. BioNTech

Bank of America

T-Mobile US

The Oracle of Omaha (and his investing team) might do a bit of shopping in the new year.

4 Stocks Warren Buffett Is Likely to Add to in 2021

Pfizer will continue to supply its COVID-19 vaccine to Italy, respecting its agreement with the European Commission, even if Rome sues the company, the chief executive of the group's Italian unit said on Thursday.

Pfizer to continue vaccine supply to Italy even if Rome files lawsuit: CEO to paper

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the fourth quarter.

Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?

Sanofi

Unusual collaboration will see Sanofi supply more than 125 million doses of Pfizer–BioNTech COVID shot from the summer.

Sanofi teams up with BioNTech and Pfizer to help fix Europe's vaccine shortage

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance (A3921133; NCT02092467). The primary objective of this study was to evaluate the safety of tofacitinib at two doses (5 mg twice daily and 10 mg twice daily) versus a TNF inhibitor (TNFi) in subjects with rheumatoid arthritis (RA) who were 50 years of age or older and had at least one additional cardiovascular (CV) risk f

Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA)

Sweden has said that it is withholding payment to the pharma giant Pfizer while it figures out if it is being overcharged for coronavirus vaccine doses. On Tuesday, the Dagens Nyheter newspaper reported that Sweden's health agency asked the European Union to ask Pfizer why it was being charged for six doses per vial of the Pfizer-BioNTech vaccine, despite only agreeing to pay for five.

Sweden is withholding vaccine payments to Pfizer as it suspects it is being overcharged

French drug maker Sanofi SA will manufacture 125 million doses of the COVID-19 vaccine co-developed by Pfizer Inc and BioNTech SE in its Frankfurt plant starting this summer.

Sanofi To Manufacture 125 Million COVID-19 Vaccine Doses For Rival Pfizer-BioNTech

But one syringe supplier said there may not be enough equipment to keep up with the pace of vaccines.

Pfizer Will Deliver Covid-19 Vaccines Much Sooner Than Expected

Pfizer will supply the US with 200 million doses of its coronavirus vaccine two months sooner than expected, according to the firm's chief executive. Pfizer CEO Albert Bourla said the US, which bought 200 million initial vaccine doses from the firm last year, will get the shipment two months earlier than expected after the FDA changed changed labels to account for "extra doses" in vials.

Pfizer will supply the US with 200 million COVID-19 vaccine doses 2 months sooner than expected due to 'extra' doses extracted from vials (PFE)

No need to let Covid-19 vaccine distribution issues deter you from owning Pfizer stock as the company still stands to earn massive revenues. The post Hold Your Pfizer Shares Despite Hiccups in Vaccine Rollout appeared first on InvestorPlace.

Hold Your Pfizer Shares Despite Hiccups in Vaccine Rollout

The European Commission approves Pfizer (PFE) and Merck KGaA's Bavencio as a monotherapy for first-line maintenance treatment in advanced/metastatic urothelial carcinoma.

Pfizer's (PFE) Bavencio Gets EU Nod for First-Line Bladder Cancer

Working with top vaccine stocks like Pfizer and BioNTech, MRVI stock is among the best IPO stocks to buy and watch as it enters a new buy zone. The post Breakout Watch: IPO Leader, Pfizer Vaccine Partner MRVI Stock Enters Buy Zone appeared first on Investor's Business Daily.

Breakout Watch: IPO Leader, Pfizer Vaccine Partner MRVI Stock Enters Buy Zone

With vaccination campaigns hindered by logistical blunders and industrial shortages, the blame game has started among European governments and industrialists.

Vaccine nationalism: Germany suggests EU should restrict the export of Pfizer's vaccine

AstraZeneca

The European Union is calling out vaccine makers AstraZeneca and Pfizer over delivery delays that could slow its recovery from the pandemic. Officials are even threatening to introduce export controls on doses produced in the bloc as anger mounts.

Pfizer and AstraZeneca take heat as vaccine delays threaten Europe's recovery

Three metrics can help answer the question.

Is Pfizer A Great Dividend Stock?

Pfizer stock was earlier a key benefactor from the coronavirus vaccine race, but a new perceptional risk is weighing on shares. The post Pfizer Faces a New Perception Risk You Shouldn't Ignore appeared first on InvestorPlace.

Pfizer Faces a New Perception Risk You Shouldn't Ignore

Recent guidance from the CEO suggests this stock will beat the market over the next decade.

Could Pfizer Be a Millionaire-Maker Stock?

The big drugmaker's coronavirus vaccine could deliver extra revenue.

Why Pfizer Will Make More Money Than Originally Expected in 2021

Pfizer (PFE) and BioNTech inks an agreement with COVAX to supply up to 40 million doses of their COVID-19 vaccine, BNT162b2.

Pfizer (PFE) to Supply 40M Doses of Coronavirus Vaccine to COVAX

"The bottom line here is that this is a very scarce resource. We need to make sure every dose gets used," Dr. Scott Gottlieb, who sits on the board of Pfizer, said.

Pfizer board member Gottlieb defends change to ship fewer Covid vaccine vials

Pfizer stock is down slightly so far this year despite an attractive valuation, high dividend yield and solid outlook. It's a value play.

News for Pfizer Stock (PFE)